<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799184</url>
  </required_header>
  <id_info>
    <org_study_id>170627010</org_study_id>
    <nct_id>NCT04799184</nct_id>
  </id_info>
  <brief_title>PK/PD Levobupivacaine With and Without Epinephrine After Ultrasound Guided ESP Block</brief_title>
  <official_title>Pharmacokinetics and Pharmacodynamics for Levobupivacaine With and Without Epinephrine After Ultrasound Guided Erector Spinae Plane Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently there is no standardized management or single technique to manage postoperative&#xD;
      pain after Video-assisted thoracic surgery (VATS), there are many options available ranging&#xD;
      from intravenous opioids, morphine or fentanyl Patient-controlled analgesia (PCA), peripheral&#xD;
      nerve blocks, intercostals, paravertebral and epidural blocks. Erector Spinal Block (ESP),&#xD;
      this blocks the ventral and dorsal branch of the unilateral thoracic roots. It corresponds to&#xD;
      an interfacial block that produces an extensive multidermatomal sensitive block with a single&#xD;
      puncture, covering the anterior, lateral and posterior aspect of the thorax. One of its main&#xD;
      advantages would be safety, possible less damage to nerves and pneumothorax, as well as the&#xD;
      simplicity of execution of this block. What has positioned it as another analgesic&#xD;
      alternative in this type of surgery.&#xD;
&#xD;
      The pharmacokinetic profile that local anesthetics would have when injected into this&#xD;
      interfacial compartment has not yet been described, and what the real impact of the use of&#xD;
      vasoconstrictor will be in terms of plasma levels and duration of the block.&#xD;
&#xD;
      Our objective is to compare the plasma levels of levobupivacaine achieved after performing an&#xD;
      ESP Block with or without epinephrine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Video-assisted thoracic surgery (VATS) is one of the most common procedures performed in&#xD;
      thoracic surgery, mainly because it has made it possible to solve many pathologies that&#xD;
      previously required a thoracotomy with all the complications that that meant. VATS has been&#xD;
      shown to be beneficial for patients, for many reasons such as lower mortality, better&#xD;
      postoperative lung function, and shorter stay during hospitalization.&#xD;
&#xD;
      Less invasive procedures such as VATS, where the surgical incision is small and avoids costal&#xD;
      resection, produces less postoperative pain when compared to a thoracotomy, this has been&#xD;
      objectified by numerous studies that have found lower scores on the numerical verbal scale&#xD;
      (NVE) and fewer requirements for pain relievers. Despite the fact that VATS produces less&#xD;
      acute postoperative pain (VNS 4-5 on the first postoperative day in VATS vs VNS 6 in&#xD;
      thoracotomies), the incidence of chronic postoperative pain ranges from 20 to 47%, which is&#xD;
      comparable to thoracotomy, mainly due to damage to the intercostal nerves and inadequate&#xD;
      analgesia.&#xD;
&#xD;
      It has been seen that one of the factors associated with the appearance of chronic pain after&#xD;
      chest surgery is severe acute pain in the first three postoperative days. Acute pain in VATS&#xD;
      is caused by surgical trauma to muscular and bone structures of the thorax, achieving good&#xD;
      analgesia is important to maintain adequate respiratory function and avoid complications such&#xD;
      as atelectasis, hypoxemia and possible pneumonia.&#xD;
&#xD;
      Currently, there is no standardized management or single technique to manage postoperative&#xD;
      pain after VATS, there are many options available ranging from intravenous opioids, morphine&#xD;
      or fentanyl Patient-controlled analgesia, peripheral nerve blocks, intercostals,&#xD;
      paravertebral and epidural blocks. Each of them with advantages and disadvantages, but&#xD;
      without being able to demonstrate a clear superiority between them, both the paravertebral&#xD;
      and epidural blocks are the ones that accumulate the most reports in the literature regarding&#xD;
      the management of postoperative pain, but at the same time they are not exempt from&#xD;
      complications such as technical failure, hypotension and difficulty of the procedure. In&#xD;
      addition to documenting a low use of thoracic epidurals in VATS.&#xD;
&#xD;
      At the end of 2016, the description of the Erector Spinal Block (ESP) by Forero was&#xD;
      published, it blocks the ventral and dorsal branch of the unilateral thoracic roots. It&#xD;
      corresponds to an interfacial block that produces an extensive multidermatomal sensitive&#xD;
      block with a single puncture, covering the anterior, lateral and posterior aspect of the&#xD;
      thorax. One of its main advantages would be safety, possible less nerve damage and&#xD;
      pneumothorax, as well as the simplicity of execution of this block. What has positioned it as&#xD;
      another analgesic alternative in this type of surgery.&#xD;
&#xD;
      In ESP, the pharmacokinetic (PK) profile that local anesthetics would have when injected into&#xD;
      this interfacial compartment has not yet been described, and what will be the real impact of&#xD;
      the use of vasoconstrictor in terms of plasma levels and duration of the block.&#xD;
&#xD;
      Considering the above, it is important to know the pharmacodynamics of levobupivacaine after&#xD;
      performing an ESP block with ultrasonography in order to know the risks of toxicity from&#xD;
      local anesthetics as well as to clinically characterize this block in patients who will&#xD;
      undergo VATS.&#xD;
&#xD;
      The first objective of this study is to compare the plasma levels of levobupivacaine achieved&#xD;
      after performing an ESP Block with or without epinephrine. As secondary objectives, it is&#xD;
      proposed to characterize the block in terms of duration, pain, opioid requirements in the&#xD;
      first 24 hours and adverse events, in both groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized into two groups, this will be done through a table of computer-generated random numbers.&#xD;
Group I will receive ESP block with vasoconstrictor and Group II will receive ESP block without vasoconstrictor.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels of levobupivacaine</measure>
    <time_frame>5, 10, 20, 30, 60, 90 minutes post block.</time_frame>
    <description>Levobupivacaine plasma levels will be measured using High-performance liquid chromatography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in plasma levels levobupivacaine of the group I v/s group II</measure>
    <time_frame>5, 10, 20, 30, 60, 90 minutes post block.</time_frame>
    <description>To assess the changes in plasma levels of the group I with epinephrine versus the group II without epinephrine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitive skin extension</measure>
    <time_frame>15 minutes post-block</time_frame>
    <description>Determine the sensitive skin extension of ESP after its performance using pinprick and temperature discrimination using an alcohol swab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain measured</measure>
    <time_frame>Every 15 minutes per 2 hours in the PACU and 12 hrs, 24 hrs, 48 hrs during hospitalization</time_frame>
    <description>Pain measured by Verbal Numerical Scale (VNS) 0 to 10. 0 = no pain. 10 = worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs.</time_frame>
    <description>Heart rate (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics</measure>
    <time_frame>Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs.</time_frame>
    <description>Invasive arterial pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse oximetry</measure>
    <time_frame>Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs.</time_frame>
    <description>% oximetry saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of morphine or its equivalents</measure>
    <time_frame>During the first 48 hours including intraoperative and postoperative</time_frame>
    <description>Consumption of morphine or its equivalents (mg/kg/hr)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Anesthetics Complications</condition>
  <condition>Anesthetic Toxicity</condition>
  <condition>Bupivacaine Overdose</condition>
  <condition>Nerve Block</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Group I Epi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ESP will be performed under ultrasound vision at T5 level, with the patient seated.&#xD;
Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% with epinephrine 5 ug/ml completing a volume of 20 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II no Epi</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The ESP will be performed under ultrasound vision at T5 level, with the patient seated.&#xD;
Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% without epinephrine completing a volume of 20 ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine 0.25% with epinephrine 5 ug/ml</intervention_name>
    <description>The block will be performed under ultrasound vision at T5 level, with the patient seated.&#xD;
Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% with epinephrine 5 ug / ml until completing a volume of 20 ml in fractional form.</description>
    <arm_group_label>Group I Epi</arm_group_label>
    <other_name>ESP</other_name>
    <other_name>Bupivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine 0.25% without epinephrine 5 ug/ml</intervention_name>
    <description>The block will be performed under ultrasound vision at T5 level, with the patient seated.&#xD;
Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% without epinephrine 5 ug / ml until completing a volume of 20 ml in fractional form.</description>
    <arm_group_label>Group II no Epi</arm_group_label>
    <other_name>ESP</other_name>
    <other_name>Bupivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Indication of VATS&#xD;
&#xD;
          -  ASA I-II&#xD;
&#xD;
          -  Body mass index (BMI) 20-34 kg / m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with conversion to thoracotomy&#xD;
&#xD;
          -  History of chronic pain&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Psychiatric illness&#xD;
&#xD;
          -  Allergic to some of the drugs used in the study&#xD;
&#xD;
          -  Chronic analgesic users&#xD;
&#xD;
          -  History of peripheral neuropathy&#xD;
&#xD;
          -  Who refuse the procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Araneda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinician</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Araneda, MD</last_name>
    <phone>223543270</phone>
    <email>andreaaraneda10@yahoo.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victor Contreras, MSN, RN</last_name>
    <phone>223549217</phone>
    <email>vecontre@uc.cl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <zip>450881</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Contreras, MSN, RN</last_name>
      <phone>223549217</phone>
      <email>vecontre@uc.cl</email>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Corvetto MA, Echevarr√≠a GC, De La Fuente N, Mosqueira L, Solari S, Altermatt FR. Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. Reg Anesth Pain Med. 2012 Nov-Dec;37(6):633-7. doi: 10.1097/AAP.0b013e31826c330a.</citation>
    <PMID>23038415</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ESP</keyword>
  <keyword>Perioperative Care</keyword>
  <keyword>Bupivacaine Overdose</keyword>
  <keyword>VATS surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug Overdose</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Procedure performance of ESP in terms of duration and user satisfaction</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>After the paper publication</ipd_time_frame>
    <ipd_access_criteria>Researchers and clinicians related to the analgesic management of patients, upon formal request via e-mail to the research director.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

